store at low temperature | store at -20 ℃
Ixekizumab (LY2439821) 是一种人源化 IgG4 单克隆抗体,可选择性结合和中和白细胞介素 IL-17A ,Kd 值<3 pM。Ixekizumab 科阻断 IL-17A 与 IL-17RA 的结合,但不与其他 IL-17 家族成员结合。Ixekizumab 用于治疗中重度斑块型银屑病、银屑病关节炎和牛皮癣。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,180 | 现货 | ||
5 mg | ¥ 3,950 | 现货 | ||
10 mg | ¥ 5,630 | 现货 | ||
25 mg | ¥ 8,650 | 现货 | ||
50 mg | ¥ 11,600 | 现货 |
产品描述 | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members.Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis and psoriasis. arthritis, and psoriasis. |
体外活性 |
Ixekizumab (0.1-10000 pM) dose-dependently inhibits the secretion of growth-regulated oncogene (GRO)α induced by human IL-17A or human IL-17A/F heterodimers from HT-29 cells. Similarly, Ixekizumab demonstrates dose-dependent inhibition of GROα secretion from HT-29 cells induced by cynomolgus monkey IL-17A.[1] The equilibrium KD values of Ixekizumab for IL-17A in humans and cynomolgus monkeys were 1.8 pM and 0.8 pM, respectively. Ixekizumab exhibited binding to rabbit IL-17A as well, although with a lower affinity and heterogeneous binding (with KD values of 1.3 nM and 14 nM, respectively). Notably, Ixekizumab did not demonstrate any binding to IL-17A in either mice or rats.[1] |
体内活性 |
Ixekizumab (0.001-1 mg/kg; i.v.; C57BL/6 mice) exhibits a dose-dependent reduction in the secretion of keratinocyte chemoattractant (KC) induced by human IL-17A in the plasma of C57BL/6 mice. In male cynomolgus monkeys, upon intravenous (IV) administration of 1 mg/kg, Ixekizumab exhibits a mean half-life of 6.5 days for elimination. Subcutaneous (SC) administration of 1 mg/kg leads to an average maximum plasma concentration of approximately 11.1 µg/mL around 72 hours after dosing. The mean elimination half-life following the SC injection was approximately 10.3 days.[1] |
别名 | LY2439821 |
分子量 | N/A |
分子式 | N/A |
CAS No. | 1143503-69-8 |
store at low temperature | store at -20 ℃
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ixekizumab 1143503-69-8 Immunology/Inflammation IL Receptor Interleukin LY 2439821 LY-2439821 LY2439821 Inhibitor inhibitor inhibit